Atara Biotherapeutics, Inc.

Atara Biotherapeutics, Inc. is a T-cell immunotherapy company focused on developing off-the-shelf treatments for cancer, autoimmune, and viral diseases. The company's lead product, tabelecleucel, is in Phase 3 clinical trials for treating epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, hematologic and solid tumors, including nasopharyngeal carcinoma. Atara is also developing next-generation CAR T immunotherapies for hematologic malignancies and solid tumors, such as ATA2271, ATA3271 for mesothelin, ATA2431, ATA3219 for B-cell malignancies, and ATA188 for multiple sclerosis. Additionally, the company has a program, ATA368, targeting human papillomavirus associated cancers.

Products

• Tabelecleucel - T-cell immunotherapy

• Next-generation CAR T immunotherapies